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Background and PurposezzUnstable carotid atherosclerotic plaques are characterized by cap 
rupture, leading to thromboembolism and stroke. Matrix metalloproteinases (MMPs) have been 
implicated in the progression of atherosclerosis and plaque rupture. The aim of this study was 
to assess the relationship between the expressions of MMP-2 and MMP-9 and carotid plaque 
instability.
MethodszzEighty atherosclerotic plaques were collected from 74 patients undergoing carotid 
endarterectomy. Clinical information was obtained from each patient, and plaque morphology 
was examined at the macroscopic and microscopic levels. The immunohistochemical expressions 
of MMPs were graded using semiquantitative scales.
ResultszzMacroscopic ulceration (84.6% versus 63.4%, p=0.042) and microscopic cap rupture 
(79.5% versus 51.2%, p=0.010) were more common in symptomatic than in asymptomatic patients. 
Immunoreactivities of MMP-2 and MMP-9 were increased in 40 and 36 atheromatous plaques, 
respectively. Macroscopic ulceration was strongly correlated with the expressions of MMP-2 
(p<0.001) and MMP-9 (p=0.001). There were significant correlations between increased MMP-
2 expression and cap rupture (p=0.002), intraplaque hemorrhage (p=0.039), and a thin fibrous 
cap (p=0.002), and between increased MMP-9 expression and cap rupture (p=0.010) and a 
large lipid core (p=0.013).
ConclusionszzPlaque rupture was significantly associated with the development of vascular 
events in carotid atherosclerotic disease. MMP-2 and MMP-9 are strongly correlated with 
plaque instability.  J Clin Neurol 2011;7:69-76
Key Wordszz  metalloproteinase, carotid plaque, instability.
Introduction
Stroke is the second most frequent cause of death in Korea. 
Moreover, the prevalence of extracranial carotid artery athero-
sclerotic disease is increasing.
1-3 The degree of carotid artery 
stenosis is known to be strongly associated with stroke risk in 
symptomatic patients with carotid atherosclerotic disease.
4-6 It 
is becoming increasingly apparent that the acute disruption of 
atherosclerotic plaques precedes the onset of clinical syn-
dromes.
7-9 Unstable plaques, characterized by cap rupture, lead 
to thromboembolism and stroke. The vulnerability of athero-
sclerotic plaques depends on many factors including endothe-
lial cell function, inflammatory cells, cytokine production, 
smooth-muscle cell content, and cell death (including necrosis 
and apoptosis).
10,11
Matrix metalloproteinases (MMPs), which are zinc-depen-
dent physiologic regulators of the extracellular matrix (ECM), 
are produced by macrophages in atherosclerotic lesions.
12 
These enzymes are capable of degrading various matrix pro-
teins and may play an important role in the development and 
progression of these lesions. Overexpression of these enzymes 
in advanced atherosclerotic lesions may contribute to thinning MMPs and Carotid Plaque Rupture
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of the plaque cap and the development of ischemic events as a 
result of plaque rupture.
13
It has been demonstrated that MMP-2 (72 kD, gelatinase A) 
and MMP-9 (92 kD, gelatinase B) cleave intact fibrillar colla-
gen, in addition to nonfibrillar and fragmented interstitial col-
lagen, and may be more important for matrix remodeling than 
previously thought.
14-16 Previous reports have described that the 
degradation of plaque collagen is significantly associated with 
increased expressions of MMP-2 and MMP-9 within the vul-
nerable regions of human atheroma.
12,17,18
In the present study, we classified morphological character-
istics according to clinical manifestation in patients with carot-
id atherosclerotic plaques. Furthermore, we evaluated differ-
ences in the patterns of expressions of MMP-2 and MMP-9 
between stable and unstable carotid plaques.
Methods
Study population
We collected carotid plaques in consecutive patients undergo-
ing carotid endarterectomy (CEA) at Kyung Hee University 
Medical Center Between January 2003 and November 2008. 
Detailed clinical information was obtained from each patient, 
with particular reference to carotid territory ischemic events. 
All patients were divided into two groups based on the timing 
of the most recent symptom. Patients with neurological symp-
toms referable to the ipsilateral carotid territory within the 12 
months before surgery were classified as symptomatic, and the 
other patients were classified as asymptomatic.
This study was approved by an independent ethics commit-
tee at Kyung Hee University Medical Center (KMC IRB 0876-
03), and informed consent to participate was obtained from all 
patients before specimen collection.
Preparation of the specimens
All operations were performed using standard surgical tech-
niques and with minimal manipulation of the specimen. Ca-
rotid plaque tissues were obtained immediately after surgical 
resection and were digitally photographed and then stored in 
0.2 M phosphate buffer solution (4°C). The tissue was cut into 
5-mm-thick blocks from the central part of the tissue where 
stenosis was maximal along the length of the plaque, using 
methods similar to those reported by Redgrave et al.
9 (Fig. 1A). 
The specimen was fixed in 4% paraformaldehyde for 24 hours 
at 4°C, and then rinsed with 30% sucrose and stored in 30% 
sucrose at 4°C for 2 days. The specimens were then embedded 
separately into an optimum cutting temperature (OCT) com-
pound (LEICA, 020108926) and stored at -80°C.
Histological analysis
All of the plaque tissues were photographed in the operating 
room just after surgical resection to allow examination of their 
gross morphology. For histological observation, 10-μm-thick 
sections were taken from each block and stained with hema-
toxylin and eosin (Fig. 1B). Histological observations were re-
corded independently by two observers who were blinded to 
clinical information. Any discrepancies between the two ob-
servers were resolved by discussion with an experienced pa-
thologist (J.H. Lee).
As in previous reports,
9,19-21 the following features were mea-
sured: cap rupture, any thrombi, intraplaque hemorrhage (IPH), 
cap thinning, a large lipid core, and calcifications (Fig. 1C, D 
and E and Supplementary Fig. 1). Cap rupture was recorded if 
there was clear communication between the lipid core and the 
lumen with a break in the fibrous cap that did not appear to have 
been created during surgery. Any thrombus was defined as an 
organized collection of fibrin and red blood cells in the lumen. 
A  
C D E
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Fig. 1. Gross and histological morphol-
ogy of a carotid specimen. A: Transverse 
sections were taken at 5-mm intervals 
and divided into central, shoulder, and 
peripheral regions. B: Results of hema-
toxylin and eosin staining (×10). C: Th-
rombus (×100). D: Rupture (×100). E: Ne-
crotic lipid core (×100).Heo SH et al.
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IPH was recorded if there was an area of erythrocytes within 
the plaque causing disruption of the plaque architecture.
22 Cap 
thinning was defined as fibrous-cap atheromas having lesions 
with a thin (<200 μm) fibrous cap and an underlying necrotic 
core.
23 A lipid core was defined as amorphous material contain-
ing cholesterol crystals. A large lipid core was defined as a lip-
id core measuring >50% of the thickness of the plaque or 
>25% of the total cross-sectional area.
24 Calcification was con-
sidered to be large when nodular deposits were seen.
25
Immunohistochemistry and  
immunofluorescence microscopy
Frozen sections were cut at a thickness of 10 μm and mounted 
on microscope slides. Tissues were fixed on silane-coated mi-
croscope slides with 99% acetone (stored at -20°C). Glycine 
was mixed in phosphate-buffered saline (PBS, pH 7.4). After 
washing three times with PBS, the microscope slides were in-
cubated with BLOTTO (100 mL of Tris-saline, 1 ml of skim 
milk, 1 ml of horse serum, and 0.02 g of azide) for 20 min.
Primary antibody, and antibodies raised against MMP-2 (sc-
71595, Santa Cruz Biotechnology) and MMP-9 (sc-21733, 
Santa Cruz Biotechnology) were diluted to 1:100, and a per-
oxidase Vector ABC kit (PK-6102, Dako) was used for their 
detection. Colocalization studies for macrophages and smooth- 
muscle cells were performed using antibodies to CD-68 
(m0851, Dako; 1:100) and smooth- muscle actin (SMA; m0876, 
Dako; 1:100), respectively. Sections were incubated in the pri-
mary antibodies for 2 hours at 37°C in an incubator. For im-
munohistochemistry, they were incubated in the secondary an-
tibody, antimouse immunoglobulin G (IgG) from the ABC kit, 
for 30 minutes at 37°C in an incubator. Diaminobenzidine was 
used as a chromogen to detect the antibodies. For immunoflu-
orescence, the sections were incubated with the secondary an-
tibody, antimouse IgG-TR (sc-2781, Santa Cruz Biotechnolo-
gy), to detect MMP-2 and MMP-9, at 37°C for 45 min in an 
incubator. After washing with PBS, the sections were mounted 
in Vectashield solution containing 4,6’diamidino-2-phenylin-
dole to stain the nuclei (H-1500, Vector Laboratories, Burlin-
game, CA, USA).
The immunohistochemical expressions of MMP-2 and 
MMP-9 were graded using the following semiquantitative 
scale: 0=no stained cells, 1=occasional scattered cells or 1 
group of ≥20 cells, 2=several groups (<5) of ≥20 cells, and 
3=many groups (≥5) of ≥20 cells or 1 group of ≥100 cells 
(Supplementary Fig. 2). There was a high interobserver agree-
ment for MMP-2 and MMP-9 (Pearson’s r=0.704 and 0.659, 
respectively). A score of 2 or more on the rating scale was clas-
sified as advanced expression.
Western blot analysis
Frozen tissue samples from four atherosclerotic plaques were 
individually homogenized in RIPA buffer (with 50% glycerol). 
Fig. 2. Carotid specimens that were im-
munohistochemically positive for MMP-
2 (A) and MMP-9 (B) were also strongly 
positive for CD68 (C) but negative for 
SMA (D). MMP: matrix metalloproteinase, 
SMA: smooth- muscle actin.
A  
C
MMP2
CD68
B
D
MMP9
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The concentration of protein was measured by enzyme-linked 
immunosorbent assay. Tissue lysate was applied to 8% sodium 
dodecylsulfate-polyacrylamide gel electrophoresis. After 
blocking with bovine serum albumin (5%) for 90 minutes, the 
primary antibodies raised against MMP-2 (sc-80201, Santa 
Cruz Biotechnology) and constitutive β-actin (sc-47778, San-
ta Cruz Biotechnology) were added (diluted to 1:500), and the 
gel was incubated overnight in a cold room (4°C) and then for 
a further hour at room temperature. The gel was then incubat-
ed with a secondary antibody (goat antimouse IgG; sc-2005, 
Santa Cruz Biotechnology) for 30 minutes. The produced 
bands were detected by a Western blotting detection system 
(luminal reagent; sc-2048, Santa Cruz Biotechnology) with 
photographic film (X-Omat, Kodak).
Statistical analysis
Patients whose most recent event was a stroke, cerebral tran-
sient ischemic attack, or amaurosis fugax were compared with 
asymptomatic patients for baseline characteristics and plaque 
histological features. Baseline demographic data are expressed 
as mean±SD values for continuous variables and as frequen-
cies for categorical variables by t-test and χ
2 test. In all tests, the 
level of statistical significance was set at p<0.05. The interra-
ter agreement was calculated by Pearson’s rho for continuous 
ratings and by Cohen’s Kappa for binominal gradings. All sta-
tistical analyses were conducted using the SPSS 13.0 package 
for Windows (SPSS, Chicago, IL, USA).
Results
In total, 108 CEAs were performed at Kyung Hee University 
Medical Center. Twenty-four specimens from atherosclerotic 
plaques were not obtained because of a lack of availability of 
immediate deliveries or the absence of informed consent. Four 
further specimens were excluded because they were too frag-
mented for morphological assessment. Eighty plaques from 74 
patients undergoing CEA were analyzed. Six patients under-
went bilateral CEA for separate ipsilateral symptomatic events 
or severe stenosis (>60%). Of 80 plaques, 41 were classified as 
asymptomatic and 39 were classified as symptomatic (transient 
ischemic attack=8, amaurosis fugax=1, and ischemic stroke= 
30). The baseline demographic features are listed in Table 1.
The age and risk factors did not differ significantly between 
Table 1. Baseline characteristics of the subjects. Data are n (%) 
values except where stated otherwise
Characteristic n (%)
Age (years; mean±SD) 66.3±8.4 
Sex (n, male/female) 57/17
Hypertension 64 (86.5)
Diabetes 28 (37.8)
Hyperlipidemia 21 (28.4)
Smoking 37 (50.0)
Coronary artery disease 20 (27.0)
Bilateral carotid operation 6 (8.1)
Clinical presentation*
Asymptomatic 41 (51.3)
Symptomatic 39 (48.8)
TIA   8 (10.0)
Amaurosis fugax 1 (1.3)
Stroke† 30 (37.5)
Location of lesion (n, right/left) 41/39
Stenosis degree (%, mean±SD) 73.2±15.1
Time since most recent ischemic event  
  in symptomatic patients
<3 months 32 (82.1)
3-6 months   5 (12.8)
6-12 months 2 (5.1)
mRS 1.2±1.2
*A total of 80 plaques from 74 patients, †Smoking: present his-
tory of smoking or quitting smoking within the previous 5 years.
TIA: transient ischemic attack, mRS: modified Rankin scale.
Table 2. Comparison of symptomatic and asymptomatic groups 
in terms of macroscopic, microscopic, and immunohistochemical 
features of carotid plaques. Data are n (%) values except where 
stated otherwise
Symptomatic
(n=39)
Asymptomatic
(n=41)
p
Clinical
Age (years; mean±SD) 64.7±8.3 67.8±7.9 0.096
Sex (n, male/female) 29/10 34/7 0.418
Hypertension 36 (92.3) 33 (80.5) 0.194
Diabetes 15 (38.5) 16 (39.0) >0.999
Hyperlipidemia 10 (25.6) 12 (29.3) 0.805
Smoking* 22 (56.4) 19 (46.3) 0.382
Coronary artery disease 10 (25.6) 10 (24.4) >0.999
Stenosis degree  
  (%, mean±SD)
77.0±15.1 69.8±14.4 0.034
Macroscopic
Plaque ulceration 33 (84.6) 26 (63.4) 0.042
Microscopic
Rupture 31 (79.5) 21 (51.2) 0.010
Thrombus 23 (56.1) 18 (43.9) 0.189
IPH 26 (66.7) 22 (53.7) 0.261
Cap thinning 27 (69.2) 23 (56.1) 0.255
Large lipid core 20 (51.3) 18 (43.9) 0.655
Calcification 33 (84.6) 30 (73.2) 0.277
Immunohistochemistry†
MMP-2 23 (56.1) 17 (41.5) 0.179
MMP-9 19 (48.7) 17 (41.5) 0.653
*Smoking: present history of smoking or quitting smoking within 
the previous 5 years, †Immunohistochemistry data are the num-
bers of plaques with advanced expression.
IPH: intraplaque hemorrhage.Heo SH et al.
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the symptomatic and asymptomatic groups. Macroscopic ul-
ceration (84.6% vs. 63.4%, p=0.042) and microscopic rupture 
(79.5% vs. 51.2%, p=0.010) were more frequent in symptom-
atic plaques than in asymptomatic plaques (Table 2). Micro-
scopic findings suggestive of marked atherosclerosis such as 
cap rupture (p<0.001), any thrombus (p=0.005), IPH (p=0.021), 
and cap thinning (p=0.038) were significantly more frequent in 
ulcerated plaques than in nonulcerated plaques. The degree of 
calcification did not differ significantly between the groups 
(p=0.363)(Table 3). For interobserver agreement, the kappa 
values for rupture (0.688), any thrombus (0.697), and IPH 
(0.697) were substantial, while those for cap thinning (0.436) 
and a large lipid core (0.506) were moderate, and that for cal-
cification (0.317) was fair.
No direct relationship was found between MMPs and clini-
cally relevant manifestations. Nevertheless, macroscopic ulcer-
ation was strongly correlated with the expressions of MMP-2 
(p<0.001) and MMP-9 (p=0.001), although the expressions of 
MMP-2 and MMP-9 did not differ significantly between the 
symptomatic and asymptomatic patient groups. Highly ex-
pressed MMP-2 and MMP-9 cells were strongly positive for 
CD68 and negative for SMA (Fig. 2). The findings of Western 
blot analyses support our immunohistochemical findings (Sup-
plementary Fig. 3). Immunofluorescence staining revealed that 
the expressions of MMP-2 and MMP-9 were colocalized with 
macrophages and stained mainly the cytoplasm (Fig. 3). In ad-
dition, there were significant correlations between increased 
MMP-2 expression and cap rupture (p=0.002), IPH (p=0.039), 
and a thin fibrous cap (p=0.002), and between increased MMP-9 
expression and cap rupture (p=0.010) and a large lipid core 
(p=0.013)(Table 4).
Discussion
We found that only plaque rupture was significantly associat-
ed with the development of vascular events in carotid athero-
sclerotic disease. In addition, the expressions of MMP-2 and 
MMP-9 were strongly related to plaque instability. The histo-
logical features of symptomatic carotid plaques were recently 
established in large clinical trials,
9,26 which found that cap rup-
ture was the only morphological feature that was significantly 
associated with the occurrence of clinical events. We confirmed 
this result in our study. In addition, the degree of stenosis was 
higher in the symptomatic than the asymptomatic group. This 
might be attributable to selection bias for surgery, that was be-
cause the degree of stenosis remained important for relevant 
ischemic events.
It has been widely accepted that plaque rupture plays a cru-
cial role in the pathogenesis of vascular events and that the de-
stabilization of atherosclerotic plaques is mediated by a series 
of enzymes called MMPs, which are the main physiological 
regulators of the ECM. Several experimental and clinical stud-
ies have established the importance of metalloproteinases in 
the critical balance between ECM breakdown and synthesis 
that determines plaque instability, leading to plaque rupture 
and other aspects of vascular remodeling.
27,28 Cell-surface ac-
tivation of MMPs is considered to be an important step in the 
pericellular degradation of the ECM during cell migration.
Increased expressions of MMP-1, -2, -3, -7, -8, -9, -10, -12, 
and -13 were found in macrophages and smooth-muscle cells 
in carotid atherosclerotic plaques.
12,23,27-32 Among these, MMP-
9 has been highlighted as one of the most important enzymes, 
and its immunostaining mostly colocalizes with macrophages 
and relates to unstable carotid plaques.
12,29 In our study, CD68 
A
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Fig. 3. Immunofluorescence staining illustrating the expressions of MMP-2 and MMP-9 produced by macrophages in carotid plaques. A and 
D: MMP-2 and MMP-9 were visualized with secondary antibodies conjugated to Texas Red (red). B and E: The nuclei were stained with DAPI 
(blue). C and F: MMPs colocalized with the cytoplasm in the macrophages. The white boxes in each image are magnified. Scale bar=100 μm. 
MMP: matrix metalloproteinase.
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cells were positive for MMPs, which suggests that macro-
phages play a role in plaque instability. These findings are con-
sistent with previously published results.
27-32 A significantly 
higher serum concentration of MMP-9 has been reported in pa-
tients with previous neurologic symptoms and unstable pla-
ques, as determined by histological analysis, and a strong cor-
relation was found between MMP-9 overexpression and the 
presence of macrophages in the plaques. However, the concen-
tration of another gelatinase, MMP-2, was only slightly higher 
in the symptomatic group than in the asymptomatic group, but 
there was no association with any of the cell types studied im-
munohistochemically.
30 Several previous studies have revealed 
that MMP-2 is not related to carotid instability, and that incre-
ased MMP-2 activity is associated with the presence of smooth-
muscle cells, suggesting a stable lesion phenotype. 
29,31,33-35 
Therefore, the relationship between MMP-2 expression and 
unstable plaques has been controversial.
We examined the expressions of MMP-2 and MMP-9 along 
with the characteristic histological plaque findings, including 
plaque rupture, any thrombus, IPH, a large lipid core, cap thin-
ning, and calcification. The findings of our study show that 
both MMP-2 and MMP-9 are significantly associated with 
plaque rupture. One previous study showed that locally pro-
duced MMP-2 is activated by thrombin and therefore increas-
es local matrix-degrading activity to complicated atheroscle-
rotic plaques, such as IPH.
36 Another study revealed that 
human monocyte-derived macrophages induce collagen break-
down in the fibrous cap of atherosclerotic plaques, thereby 
contributing to cap thinning and weakening by MMP-1 and 
MMP-2.
18 Moreover, a large lipid core was related only to 
MMP-9. By measuring the MMP-9 level as a marker of plaque 
instability, recent studies have demonstrated that increased 
levels of oxidized low-density lipoprotein are markedly asso-
ciated with MMP-9 activation, and that statins reduce inflam-
matory responses.
37,38
Our study has several clear advantages. First, even though 
there are only a few previous reports on the histopathological 
characteristics of carotid plaques in Asian patients,
34,39 we per-
formed careful clinicohistopathological correlations, and con-
firmed that plaque morphology determines the propensity to 
provoke clinical manifestations. Second, we described the his-
tological findings and the association with MMPs in detail. We 
performed a histological analysis, satisfying the recommenda-
tions for the performance and reporting of studies of carotid 
plaque imaging with histology proposed by Lovett et al.
40
Our study was subject to some limitations. First, we ana-
lyzed our results semiquantitatively by immunohistochemis-
try, and hence the results do not readily allow accurate quanti-
fication. Nevertheless, our estimates were performed by two 
observers, and the interobserver reliability was high. Second, 
the target site that we selected from the experimental speci-
mens was the central (cap and core) region of the carotid 
plaque, because the focus of this study was plaque rupture. 
According to previous studies, MMPs are expressed primarily 
by macrophages in the shoulder regions of the atherosclerotic 
plaque and in the border between the lipid core and the overly-
ing fibrous area.
12,32 Thus, it is possible that we excluded the 
regions of the plaques where inflammation is likely to take 
place (i.e., the shoulder).
These results have important implications not only with re-
spect to our understanding of the processes that lead to acute 
cerebral ischemia due to carotid plaques, but also with regard 
to the interpretation of the topographic appearance of plaques. 
Our results confirm the associations of MMP-2 and MMP-9 
with plaque instability. In the future, the use of high-through-
Table 4. Prevalence of histological features in plaques with immunohistochemistry results. Data are n (%) values except where stated oth-
erwise
MMP-2
p
MMP-9
p
Positive (n=40) Negative (n=40) Positive (n=36) Negative (n=44)
Rupture 33 (82.5) 19 (47.5) 0.002 29 (80.6) 23 (52.3) 0.010
Thrombus 22 (55.0) 19 (47.5) 0.655 21 (58.3) 20 (45.5) 0.271
IPH 29 (72.5) 19 (47.5) 0.039 23 (63.9) 25 (56.8) 0.647
Cap thinning 32 (80.0) 18 (45.0) 0.002 25 (69.4) 25 (56.8) 0.353
Large lipid core 23 (57.5) 15 (37.5) 0.117 23 (63.9) 15 (34.1) 0.013
Calcification 33 (82.5) 30 (75.0) 0.586 30 (83.3) 33 (75.0) 0.420
Table 3. Prevalence of histological features in plaques with mac-
roscopic ulceration. Data are n (%) values except where stated 
otherwise
Ulceration
(n=59)
No ulceration 
(n=21)
p
Rupture 47 (79.7) 05 (23.8) <0.001
Thrombus 36 (61.0) 05 (23.8) <0.005
IPH 40 (67.8) 08 (38.1) <0.021
Cap thinning 41 (69.5) 09 (42.9) <0.038
Large lipid core 32 (54.2) 06 (28.6) <0.074
Calcification 48 (81.4) 15 (71.4) <0.363
MMP-2 38 (64.4) 2 (9.5) <0.001
MMP-9 33 (55.9) 03 (14.3) <0.001Heo SH et al.
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put techniques will potentially identify novel patterns of bio-
markers that, along with traditional risk factors and imaging 
techniques, could help to target vulnerable patients and moni-
tor the beneficial effects of pharmacological agents.
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